Life sciences glossary C–D

The following Life Sciences practice note provides comprehensive and up to date legal information covering:

  • Life sciences glossary C–D
  • CE marking
  • Centralised procedure
  • Clinical data
  • Clinical evaluation
  • Clinical investigation
  • Clinical investigation plan
  • Clinical study
  • Clinical trial
  • Clinical Commissioning Groups (CCGs)
  • More...

Life sciences glossary C–D

IP COMPLETION DAY: The Brexit transition period ended at 11pm on 31 December 2020. At this time (referred to in UK law as ‘IP completion day’), transitional arrangements ended and significant changes began to take effect across the UK’s legal regime. This document contains guidance on subjects impacted by these changes. Before continuing your research, see Practice Note: What does IP completion day mean for Life Sciences?

A–B | E–H | I–N | O–P | Q–U.

CE marking

The CE (Conformité Européene—meaning European Conformity) mark is a mandatory conformity marking for certain products sold within the EEA, including medical devices. It:

  1. shows that the manufacturer has checked that these products meet EU safety, health or environmental requirements

  2. is an indicator of a product’s compliance with EU legislation

  3. allows the free movement of products within the European market

See Practice Note: An introduction to the regulation of medical devices.

Centralised procedure

One of the procedures available for the authorisation of medicinal products in the EU. It is the mandatory procedure for the following types of medicinal products: products derived from biotechnology, for orphan medicinal products and for medicinal products for human use which contain an active substance authorised in the Community after 20 May 2004 (date of entry into force of Regulation (EC) 726/2004, the EMA Regulation (consolidated version)) and which are intended for the treatment of AIDS, cancer, neurodegenerative disorders

Popular documents